Hospira

NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Eli Lilly, CFO, Acquisition, OPCH, Mallinckrodt, Syneos Health, Hospira, SVP, OTC, ENOV, Growth, BioMarin Pharmaceutical, MBA, Hill-Rom, NorthStar, CDMO, Doctor of Philosophy, University, Engineering, Partnership, Radiopharmaceutical, McKinsey & Company, Patient, Invacare, IVC, Northwestern University, Health technology, Cancer, Management

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.

Key Points: 
  • NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.
  • "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar.
  • She is currently a Board Director for Enovis Corporation (NYSE: ENOV), Option Care Health (NASDAQ: OPCH) and BioMarin Pharmaceutical (NASDAQ: BMRN).
  • “2024 and the next few years will be critical for NorthStar,” said Frank Scholz, Ph.D., NorthStar President and Chief Executive Officer.

Pulse Health Unveils Request a Rep, a Seamless Connection Between Engaged HCPs and Relevant Field Force Reps

Retrieved on: 
Tuesday, January 16, 2024
Cloud, Software as a service, HCP, Communication, Software, Marketing, Pulse, Automation, Hospira, Sales

NEW YORK, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Today, Pulse Health announced the launch of Request a Rep, providing pharma with cutting-edge technology to seamlessly capture, analyze and connect HCPs that visit a brands website with the most relevant field force reps.

Key Points: 
  • Delivering significant innovation to the life science industry, Request a Rep can be leveraged within the Pulse Engagement Cloud or as a standalone product.
  • Historically, when a healthcare provider visited a brand's website and requested information, they entered a general database.
  • With Request a Rep enabled, Pulse leverages its proprietary technology to analyze the captured data and direct it to the most relevant field force representative.
  • This all-in-one Software as a Service (SaaS) solution effortlessly integrates marketing automation, advanced segmentation, centralized databases, omni-channel marketing, and brand-specific analytics and insights.

Sail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D’Amelio to Its Board

Retrieved on: 
Thursday, January 4, 2024
Software, Research, General Health, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, RNA, Panasonic Executive Partner, Sale, CFO, Messenger, KKR, Acquisition, Medivation, Flagship Pioneering, MBA, Capsugel, Hospira, Biomedicine, Growth, Lucent, Management

Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.

Key Points: 
  • Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.
  • At Lucent, he played a critical role in its spinout from AT&T.
  • “I’m honored to be joining the Sail Biomedicines Board of Directors at a pivotal time for the company,” said Mr. D’Amelio.
  • “Sail’s vision and platform, which builds on over eight years of experimentation, represents an exciting opportunity to generate new medicines and forge innovative relationships with partners.

Biotech Veteran Marc Yoskowitz Named Evozyne CEO

Retrieved on: 
Thursday, January 4, 2024
Professional Services, Health, Technology, Finance, General Health, Artificial Intelligence, Biotechnology, Paragon, Pfizer, McKinsey & Company, Drug discovery, Protein, OrbiMed, Hospira, Tempus, Patient, NVIDIA

Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.

Key Points: 
  • Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.
  • Yoskowitz has held executive leadership positions with Pfizer, Hospira and McKinsey & Company, bringing deep biopharmaceutical, corporate development and strategy expertise to the role.
  • Leading a company that is pioneering this technology and developing novel proteins is an unparalleled opportunity,” Yoskowitz said.
  • Founded in 2020 by Paragon Biosciences, Evozyne develops novel proteins that solve high-impact problems in human health.

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Retrieved on: 
Wednesday, December 20, 2023
Adverum Biotechnologies, University, Ambit Biosciences, Daiichi Sankyo, Hill-Rom, Indiana University, Harvard Law School, Baxter, Acceleration, Strategy, Palmer, Pfizer, Biotechnology Innovation Organization, Invacare, Eli Lilly, Hospira, Pediatrics, Chairperson, The Nature Conservancy, Genzyme, American Cancer Society, Therapy, Goldman Sachs, M.B.A, BMRN, ImmunoGen, DSM-IV codes, Shire (pharmaceutical company), IPO, Patient, Proteostasis, BioMarin Pharmaceutical, Corporate development, Dentsply Sirona, Senior, Syneos Health, Iovance Biotherapeutics, Sclerosis, Acquisition, SAN, CIO, Eli Lilly and Company, Interim, Bristol Myers Squibb, Information technology, Management

SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Key Points: 
  • SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.
  • "Today's announcements will strengthen our ability to drive better outcomes for patients with genetic diseases and deliver value to all stakeholders.
  • BioMarin plays a pivotal role in the treatment of genetic diseases thanks to its globally leading rare-disease portfolio.
  • We believe the changes announced today put BioMarin in the best position to realize its full potential, and we support Alexander Hardy as the right leader for this chapter of BioMarin's value creation story.

BioFlorida Appoints Mark A. Glickman as President & CEO to Continue to Propel Florida's Life Sciences Community Forward

Retrieved on: 
Monday, December 4, 2023
Auxilium, Esperion Therapeutics, Sale, Principal, Esperies, Negotiation, Research, Therapy, Patient, MBA, Retirement, PALM, Growth, Hospira, Human, Management, Fine chemical, Capitol

WEST PALM BEACH, Fla., Dec. 4, 2023 /PRNewswire/ -- BioFlorida, the leading voice of Florida's life sciences industry, announced that Mark A. Glickman, MBA, will serve as its new President and Chief Executive Officer.

Key Points: 
  • WEST PALM BEACH, Fla., Dec. 4, 2023 /PRNewswire/ -- BioFlorida, the leading voice of Florida's life sciences industry, announced that Mark A. Glickman, MBA, will serve as its new President and Chief Executive Officer.
  • A longstanding member of Florida's life sciences community, Mr. Glickman brings over 30 years of experience and leadership to BioFlorida.
  • "We are thrilled to welcome Mark Glickman as BioFlorida's new President and CEO," said Robert Finizio, Chairman of the Board for BioFlorida.
  • Mark Glickman will officially assume the role of President and CEO of BioFlorida on December 9, 2023.

Fortune Brands Appoints Kristin Papesh as Chief Human Resources Officer; Sheri Grissom to Continue Leading Company’s Transformation Management Office

Retrieved on: 
Friday, October 27, 2023
Commercial Building & Real Estate, Construction & Property, Specialty, Interior Design, Home Goods, Building Systems, Architecture, Retail, Residential Building & Real Estate, Hospira, NYSE, Fortune Brands, Medicine, Fink, Human resources, Development, Senior, Pfizer, Growth, Executive, Walgreens Boots Alliance, HR, Chief business officer, Management

Additionally, Sheri Grissom, the Company’s current Chief Human Resources and Transformation Officer, will solely focus on leading the Company’s Transformation Management Office in her role of Executive Vice President and Chief Transformation Officer beginning November 27, 2023.

Key Points: 
  • Additionally, Sheri Grissom, the Company’s current Chief Human Resources and Transformation Officer, will solely focus on leading the Company’s Transformation Management Office in her role of Executive Vice President and Chief Transformation Officer beginning November 27, 2023.
  • “I am pleased to welcome Kristin to our leadership team as Chief Human Resources Officer.
  • Grissom has led Fortune Brands’ Human Resources team since 2015, and will transition to serve solely as Chief Transformation Officer beginning on November 27, 2023.
  • Sheri, who has built Fortune Brands’ HR function, will now be dedicated to driving change through our Transformation Management Office.

Komodo Health Appoints Julia Goebel, Brad Kelley to Senior Marketing and Data Strategy Positions

Retrieved on: 
Tuesday, October 3, 2023
Technology, Biotechnology, Health, Venture Capital, Other Health, Professional Services, Marketing, Software, General Health, Data Analytics, Communications, Health Technology, Data Management, Security, University, Senior, Executive education, Risk management, Journalism, Washington University in St. Louis, Eli Lilly, Organization, Cardinal Health, Bachelor of Arts, State, Express Scripts, Patient, Growth, Entrepreneurship, Hospira, Julia, Electricity, Pfizer, Disease, Pharmaceutical industry, Science, Cigna, Economics, Komodo

Julia Goebel was named Senior Vice President of Marketing, and Brad Kelley was named General Manager of MapEnhance.

Key Points: 
  • Julia Goebel was named Senior Vice President of Marketing, and Brad Kelley was named General Manager of MapEnhance.
  • As Komodo’s new head of marketing, Julia will deepen the company’s strategic approach to key customer segments, optimizing market awareness for Komodo’s unique full-stack technology strategy and differentiated data and technology products.
  • She will bring to Komodo her extensive marketing experience in software and subscription businesses, both publicly traded and privately held.
  • “I am thrilled to welcome both Julia and Brad to Komodo,” said Web Sun, Co-Founder and President of Komodo Health.

Letter to Shareholders and Corporate Update

Retrieved on: 
Monday, September 11, 2023
Highbridge, Letter, Partnership, Therapy, Marketing, API, Woman, Hospira, Fertilisation, Sale, MITRA, EUR, CDMO, CEST, Brussels Stock Exchange, Menopause, White box, Management, Financial services, Pharmaceutical industry, Estetrol

Liege, Belgium, 11 September 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”), today published a Letter to Shareholders and Corporate Update from Chief Executive Officer, Dr. David Horn Solomon.

Key Points: 
  • Liege, Belgium, 11 September 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”), today published a Letter to Shareholders and Corporate Update from Chief Executive Officer, Dr. David Horn Solomon.
  • We raised EUR 20 million in a successful equity financing, with potential for up to an additional EUR 45 million in equity.
  • I hope that you will agree that these achievements are significant and consistent with the strategy we set forth in our shareholder letter in May.
  • Mithra’s executive leadership is working closely and in lock-step with our Board of Directors to execute on our strategy.

Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride for Injection Concentrate, USP

Retrieved on: 
Tuesday, August 15, 2023
Other Manufacturing, FDA, Manufacturing, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, CGT, Hospira, Food and Drug Administration, USP, RLD, Federal Food, Drug, and Cosmetic Act, Potassium chloride, FD, Food, Pharmaceutical industry, Nexus

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride for Injection Concentrate, USP in 10mL and 20mL Single-Dose Vials.

Key Points: 
  • Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride for Injection Concentrate, USP in 10mL and 20mL Single-Dose Vials.
  • According to the FDA and the FD&C (Federal Food, Drug, and Cosmetic) Act, the product is considered bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Potassium Chloride for Injection Concentrate, USP, of Hospira, Inc.
  • “This approval highlights Nexus’ commitment to stabilizing the domestic pharmaceutical supply chain,” said Usman Ahmed, President and CEO of Nexus.
  • “Potassium Chloride for Injection Concentrate has been on the FDA’s drug shortage list for several years and we are very proud to alleviate this shortage with a product manufactured in the United States.